934264-38-7
Chemical Structure
Bentysrepinine
Synonym(s): Y101
- CAS No.: 934264-38-7
- Formula:C29H35N3O4
- Molecular Weight:489.61
IUPAC Name: N-((S)-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(((S)-1-hydroxy-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)benzamide
InChIKey: XWEMGJQQCSSGPN-BDYUSTAISA-N
SMILES: CN(C)CCOC(C=C1)=CC=C1C[C@H](NC(C2=CC=CC=C2)=O)C(N[C@H](CO)CC3=CC=CC=C3)=O
Biological Activity: Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bentysrepinine | Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Fan H, et al. Metabolite identification of bentysrepinine (Y101), a novel anti-HBV agent in rats using a five-step strategy based on a combined workflow with two different platforms of liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:118-128. [Content Brief]
- [2]. Fan H, et al. In vitro metabolism and in vivo pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison. Xenobiotica. 2020 Apr;50(4):468-478. [Content Brief]
Keywords
